After Regeneron’s co-founders cleared 2020 with a potential $260 million in stock awards that could be cashed out in a few years, the total salary for the pair of billionaires has come down from its sky high perch.

CEO Len Schleifer and CSO George Yancopoulos, the pair at the forefront of the 34-year-old pharma, each earned approximately $6.4 million in 2021, putting them on the low side of CEO and top exec payouts in their industry. And for American pharmas, it puts the pair even lower on the pay totem pole compared to substantially larger pharma companies like J&J. Alex Gorsky, the former CEO and now executive chairman, brought in more than $26 million in pay and perks for 2021.

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The Endpoints News team is really growing. We’re excited to welcome Lei Lei Wu and Tyler Patchen joining as our newest reporters. For an illustration of what a diverse set of writers could bring, look no further than this year’s Endpoints 20 under 40 — the perspectives and accents that everyone brings are simply incredible. I hope you enjoy reading the special report as much as I did.

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

Voyager Therapeutics was able to poach Al Sandrock out of his very, very brief retirement from Biogen to right its wavering gene therapy ship after a rocky first nine years. But a month into his journey, two of Sandrock’s fellow board members don’t want to be reelected.

One of those is Voyager’s own co-founder and former CEO Steven Paul. The other is Mark Levin, the Millennium co-founder and an original member of Third Rock Ventures, the VC firm that launched Voyager in 2013.

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

A panel of FDA’s outside advisors unanimously voted, with one abstention, that future approvals of PI3K inhibitors should be supported by randomized data.

The 17-member ODAC panel was asked by federal regulators to discuss observed toxicities of the Phosphatidylinositol-3-kinase inhibitor class and whether randomized survival data are needed to support risk-benefit evaluations in patients with blood cancers. They returned, after listening to agency presenters, with a resounding “Yes.”

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

A Catholic order of nuns and an investment organization are pushing several big pharma companies to be more transparent around their wheeling and dealing on Capitol Hill.

The Maryknoll Sisters of St. Dominic, a group of Roman Catholic nuns based in Ossining, New York, and a Vancouver-based association of institutional investors known as the Shareholder Association for Research and Education, want to establish third-party reviews of the lobbying activity for Johnson & Johnson, Gilead and Eli Lilly.

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

What is CMV? If you’re like most people, you don’t know. Moderna wants to change that, especially for women ages 16-40 because CMV, or cytomegalovirus, is the leading infectious cause of birth defects in the US.

Moderna — currently in a Phase III study of its proposed CMV vaccine — is running a social and digital campaign including mom influencers and partnerships with popular media aimed at the target audience. Its campaign home website, “Now I Know CMV” includes facts and figures about CMV along with outside resource links to the Centers for Disease Control and the American Academy of Pediatrics. It also includes a link to a pre-screening and sign-up website for Moderna’s clinical trial, with a modern stylized “We Vs. CMV” theme.

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

What happens when the FDA tells a company to pull a drug approved under its accelerated pathway because it didn’t prove to be effective in a confirmatory trial, and the company refuses?

That’s what is currently playing out between the FDA and Covis Pharma, which will duel it out during a final two-and-a-half-day virtual hearing set for next September or October, according to the latest letter from Celia Witten, FDA’s director of the Office of Cellular, Tissue and Gene Therapy and who’s presiding over the hearing.

On Thursday, the World Health Organization made a strong recommendation for Pfizer’s pill Paxlovid for use in mild and moderate Covid-19 patients.

However, the WHO also raised concerns about the availability, the lack of price transparency and the need for quick and accurate testing before being administered. This presents a challenge for low- and middle-income nations, according to the WHO.

In another blow to Biogen’s controversial Alzheimer’s drug, the company has decided to pull its application for the drug in Europe after regulators there rejected it late last year.

In making the decision, the EMA explained how, although Aduhelm (aducanumab) reduces amyloid beta in the brain, the link between this effect and clinical improvement has not been established.

The FDA famously signed off on the drug last June under an accelerated approval that allows for this confirmatory clinical benefit to be established at a later date, although the Centers for Medicare and Medicaid Services have since finalized a decision to not pay for use of the Aduhelm outside of clinical trials, severely restricting any immediate sales of the drug.

After repeated setbacks in gene therapy, Astellas is writing off more than half a billion dollars in losses — and gutting candidates that were once thought to have massive potential.

Astellas said in a statement Friday that it is booking an “impairment loss” over two fiscal quarters: Q4 of the last fiscal year ending March 31, 2022, and Q1 of the new fiscal that started April 1. The total loss? Just under $390 million for Q4, and $170 million for the new quarter.

Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it's free.

Bioscience & Technology Business Center The University of Kansas Lawrence, Kansas

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET